Peptidomimetic antibiotics disrupt the lipopolysaccharide transport bridge of drug-resistant Enterobacteriaceae.


Journal

Science advances
ISSN: 2375-2548
Titre abrégé: Sci Adv
Pays: United States
ID NLM: 101653440

Informations de publication

Date de publication:
24 05 2023
Historique:
medline: 26 5 2023
pubmed: 24 5 2023
entrez: 24 5 2023
Statut: ppublish

Résumé

The rise of antimicrobial resistance poses a substantial threat to our health system, and, hence, development of drugs against novel targets is urgently needed. The natural peptide thanatin kills Gram-negative bacteria by targeting proteins of the lipopolysaccharide transport (Lpt) machinery. Using the thanatin scaffold together with phenotypic medicinal chemistry, structural data, and a target-focused approach, we developed antimicrobial peptides with drug-like properties. They exhibit potent activity against Enterobacteriaceae both in vitro and in vivo while eliciting low frequencies of resistance. We show that the peptides bind LptA of both wild-type and thanatin-resistant

Identifiants

pubmed: 37224246
doi: 10.1126/sciadv.adg3683
pmc: PMC10208570
doi:

Substances chimiques

Lipopolysaccharides 0
Peptidomimetics 0
Anti-Bacterial Agents 0
LptA protein, E coli 0
Carrier Proteins 0
Escherichia coli Proteins 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

eadg3683

Références

Biochim Biophys Acta Biomembr. 2022 Mar 1;1864(3):183839
pubmed: 34915021
Nat Chem Biol. 2021 Feb;17(2):187-195
pubmed: 33199913
J Biomol NMR. 2001 May;20(1):11-4
pubmed: 11430750
Lancet Infect Dis. 2018 Mar;18(3):318-327
pubmed: 29276051
Eur J Biochem. 1998 Sep 1;256(2):404-10
pubmed: 9760181
Science. 2010 Feb 19;327(5968):1010-3
pubmed: 20167788
Sci Adv. 2018 Nov 14;4(11):eaau2634
pubmed: 30443594
Chem Rev. 2021 May 12;121(9):5098-5123
pubmed: 32955879
Lancet. 2022 Feb 12;399(10325):629-655
pubmed: 35065702
J Bacteriol. 2008 Jul;190(13):4460-9
pubmed: 18424520
Biochim Biophys Acta Biomembr. 2020 Oct 1;1862(10):183354
pubmed: 32413443
Sci Rep. 2017 Aug 29;7(1):9715
pubmed: 28852068
Nature. 2019 Dec;576(7787):452-458
pubmed: 31645764
Nature. 2020 Aug;584(7821):479-483
pubmed: 32788728
Proc Natl Acad Sci U S A. 1996 Feb 6;93(3):1221-5
pubmed: 8577744
Clin Microbiol Infect. 2014 Sep;20(9):862-72
pubmed: 24890393
mBio. 2020 Apr 14;11(2):
pubmed: 32291302
Science. 2018 Feb 16;359(6377):798-801
pubmed: 29449493
Front Microbiol. 2020 May 13;11:909
pubmed: 32477309
Methods Mol Biol. 2004;278:353-78
pubmed: 15318003
Mol Microbiol. 2014 Jan;91(1):145-57
pubmed: 24266962
J Biomol NMR. 2013 Jul;56(3):227-41
pubmed: 23728592
Protein Sci. 2018 Feb;27(2):381-389
pubmed: 29024084
Clin Infect Dis. 2009 Jan 1;48(1):1-12
pubmed: 19035777
Proc Natl Acad Sci U S A. 2019 Oct 22;116(43):21748-21757
pubmed: 31591200
Biochim Biophys Acta Mol Cell Biol Lipids. 2017 Nov;1862(11):1451-1460
pubmed: 27760389
J Chem Theory Comput. 2012 Sep 11;8(9):3257-3273
pubmed: 23341755
Q Rev Biophys. 1990 Feb;23(1):39-96
pubmed: 2160666
Protein Sci. 2018 Aug;27(8):1407-1417
pubmed: 29672978
Chem Rev. 2021 Mar 24;121(6):3464-3494
pubmed: 33606500
Biochem Biophys Res Commun. 2008 May 2;369(2):609-15
pubmed: 18294955
Nature. 2019 Dec;576(7787):459-464
pubmed: 31747680

Auteurs

Matthias Schuster (M)

University of Zürich, Winterthurerstrasse 190, CH-8057 Zürich, Switzerland.

Emile Brabet (E)

Spexis AG, Hegenheimermattweg 125, CH-4112 Allschwil, Switzerland.

Kathryn K Oi (KK)

University of Zürich, Winterthurerstrasse 190, CH-8057 Zürich, Switzerland.

Nicolas Desjonquères (N)

Spexis AG, Hegenheimermattweg 125, CH-4112 Allschwil, Switzerland.

Kerstin Moehle (K)

University of Zürich, Winterthurerstrasse 190, CH-8057 Zürich, Switzerland.

Karen Le Poupon (K)

Spexis AG, Hegenheimermattweg 125, CH-4112 Allschwil, Switzerland.

Sophie Hell (S)

Spexis AG, Hegenheimermattweg 125, CH-4112 Allschwil, Switzerland.

Stéphane Gable (S)

Spexis AG, Hegenheimermattweg 125, CH-4112 Allschwil, Switzerland.

Virginie Rithié (V)

Spexis AG, Hegenheimermattweg 125, CH-4112 Allschwil, Switzerland.

Séverine Dillinger (S)

Spexis AG, Hegenheimermattweg 125, CH-4112 Allschwil, Switzerland.

Peter Zbinden (P)

Spexis AG, Hegenheimermattweg 125, CH-4112 Allschwil, Switzerland.

Anatol Luther (A)

Spexis AG, Hegenheimermattweg 125, CH-4112 Allschwil, Switzerland.

Claudia Li (C)

Spexis AG, Hegenheimermattweg 125, CH-4112 Allschwil, Switzerland.

Sarah Stiegeler (S)

Spexis AG, Hegenheimermattweg 125, CH-4112 Allschwil, Switzerland.

Carolin D'Arco (C)

Spexis AG, Hegenheimermattweg 125, CH-4112 Allschwil, Switzerland.

Hans Locher (H)

Spexis AG, Hegenheimermattweg 125, CH-4112 Allschwil, Switzerland.

Tobias Remus (T)

Spexis AG, Hegenheimermattweg 125, CH-4112 Allschwil, Switzerland.

Selena DiMaio (S)

Spexis AG, Hegenheimermattweg 125, CH-4112 Allschwil, Switzerland.

Paola Motta (P)

Spexis AG, Hegenheimermattweg 125, CH-4112 Allschwil, Switzerland.

Achim Wach (A)

Spexis AG, Hegenheimermattweg 125, CH-4112 Allschwil, Switzerland.

Françoise Jung (F)

Spexis AG, Hegenheimermattweg 125, CH-4112 Allschwil, Switzerland.

Grégory Upert (G)

Spexis AG, Hegenheimermattweg 125, CH-4112 Allschwil, Switzerland.

Daniel Obrecht (D)

Spexis AG, Hegenheimermattweg 125, CH-4112 Allschwil, Switzerland.

Mohammed Benghezal (M)

Spexis AG, Hegenheimermattweg 125, CH-4112 Allschwil, Switzerland.

Oliver Zerbe (O)

University of Zürich, Winterthurerstrasse 190, CH-8057 Zürich, Switzerland.

Articles similaires

Vancomycin-associated DRESS demonstrates delay in AST abnormalities.

Ahmed Hussein, Kateri L Schoettinger, Jourdan Hydol-Smith et al.
1.00
Humans Drug Hypersensitivity Syndrome Vancomycin Female Male
Humans Arthroplasty, Replacement, Elbow Prosthesis-Related Infections Debridement Anti-Bacterial Agents
Vancomycin Polyesters Anti-Bacterial Agents Models, Theoretical Drug Liberation
Animals Humans Sarcomeres Muscle Proteins Carrier Proteins

Classifications MeSH